‘Omics’ technologies developed for the massive analysis of the major biologically relevant molecules (genes, proteins, metabolites) have been applied to the study of osteoarthritis (OA) for more than a decade.
‘Omics’ studies have undoubtedly contributed to increase the knowledge on pathogenic processes related with OA and have provided hundreds to thousands of molecules that might have a putative biomarker utility for this disease.
This review describes the most recent ‘omics’ studies in OA research, their conclusions, and discuss those remaining challenges. Still many validation studies must be performed in large and well-characterized cohorts for the translation of the findings from ‘omics’ strategies to clinical applications. The development of tools for the intelligent integration of ‘omics’ data with clinical and imaging information is also mandatory to take full profit of the work that has been already performed.
aRheumatology Division, ProteoRed/ISCIII Proteomics Group, INIBIC – Hospital Universitario de A Coruña
bCIBER-BBN Instituto de Salud Carlos III, INIBIC-CHUAC
cRIER-RED de Inflamación y Enfermedades Reumáticas, INIBIC-CHUAC
dRheumatology Division, Genomics Group, INIBIC – Hospital Universitario de A Coruña, 15006 A Coruña, Spain
Correspondence to Francisco J. Blanco, MD, PhD, INIBIC-Complejo Hospitalario Universitario A Coruña, C/ Xubias, 84, 15006-A Coruña, Spain. Tel: +34 981 176399; fax: +34 981 176398; e-mail: firstname.lastname@example.org